The Sanofi Foundation has announced a renewed focus on supporting children and young people, especially those with serious illnesses. It plans to invest €15 million annually in programs that improve early diagnosis, care, and social inclusion, partnering with organizations like the Cerebral Palsy Foundation and AIDA. The foundation also continues its humanitarian work, having impacted over 26 million patients across 45 countries, and aims to positively affect over 6 million children and youth by 2030. This shift underscores Sanofi's commitment to addressing broader health, climate, and social challenges faced by younger generations.
The Sanofi Foundation is enhancing its focus on supporting children and young people, especially those with serious illnesses, by allocating an annual budget of €15 million. The foundation partners with NGOs and healthcare groups to improve early dia...
The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...
The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial res...
Japan's Ministry of Health has approved Sanofi's Wayrilz (rilzabrutinib), a novel oral BTK inhibitor, for treating persistent or chronic immune thrombocytopenia (ITP) in patients unresponsive or intolerant to other treatments. The approval is based o...
Sanofi has named Paulo Fontoura as its new Executive Vice President and Global Head of Research & Development Pharma, effective September 1, 2026. Fontoura brings over 25 years of experience in medicine and pharmaceutical innovation, having held seni...
